2025 Adult Rheumatology Fellowship Match is Strong (Again)
ACR
Recent News
Read ArticleThe American College of Rheumatology (ACR) announced today that 2025 Medicine and Pediatric Specialties Match results show rheumatology fellowship positions continuing to fill at high rates. The Match uses a computerized process to pair applicant and program preferences, determining where physicians will complete subspecialty training.
Metabolic Bone Pearls
Betsy Kirchner, DNP, shares practical tips for managing metabolic bone disease, including the importance of VFA imaging to catch asymptomatic vertebral fractures and utilizing fracture liaison services to close care gaps. She highlights key pearls like the doubled fracture risk in RA patients, ACR's risk stratification for glucocorticoid-induced osteoporosis, and a simple FRAX adjustment calculation that can improve treatment decisions.
Read Article
ICYMI: MSK Evaluation
https://t.co/QuHWcv6zAc https://t.co/0n5A1EtL9c
Dr. John Cush @RheumNow ( View Tweet)
B Cell Targeting in Idiopathic Thrombocytopenic Purpura
The New England Journal of Medicine has published a phase III clinical trial showing that a B cell targeting monoclonal antibody, ianalumab, was effective in more than half of the patients with primary immune https://t.co/VN0KjE478B
Dr. John Cush @RheumNow ( View Tweet)
I Can't Believe it's Not Seronegative Rheumatoid Arthritis?!
In rheumatology, we're no stranger to uncertainty. In any diagnosis of seronegative rheumatoid arthritis, it's always our invitation to reconsider the diagnosis.
https://t.co/JGPTXkvF3E https://t.co/ds1aRzAPF7
Dr. John Cush @RheumNow ( View Tweet)
FDA has issued its final guidance on: Promotional Labeling and Advertising Considerations for Prescription Biological Reference Products, Biosimilar Products, and Interchangeable Biosimilar Products: Questions and Answers https://t.co/69sbgoWnSW https://t.co/kpTgdPOkka
Dr. John Cush @RheumNow ( View Tweet)
FDA has issued its final guidance on: Promotional Labeling and Advertising Considerations for Prescription Biological Reference Products, Biosimilar Products, and Interchangeable Biosimilar Products: Questions and Answers https://t.co/bjiV4S0Fur https://t.co/dDyJqhV5VF
Links:
Dr. John Cush @RheumNow ( View Tweet)
China cross-sectional cohort study of 10658 gout pts, showed betw 2003-22, gout onset age signif declined (42 to 38.9 yrs) w/ 6% incr in ≤19 and 9.6% ince in 20–29 yrs. Younger onset also assoc w/ gout severity(tophi, flares, Kstones) & more HTN, DM, less dyslipidemia https://t.co/XczvWr0xZl
Dr. John Cush @RheumNow ( View Tweet)
Medical Cannabis for Pain Management
Recent research and publications have underscored the use, efficacy, safety and limitations to the use of cannabis for arthritis and pain patients.
Read Article
The countdown is on! ⏱️
Drs. Jack Cush & Artie Kavanaugh are previewing what’s coming to RheumNow Live 2026 in Dallas (Feb 7–8) – and you don’t want FOMO on this one.
✅ Register now at https://t.co/4UQlqwujiR
🔥Early bird pricing ends December 15 – Get the inside scoop on https://t.co/K6kxX2oDtu
Links:
Dr. John Cush @RheumNow ( View Tweet)
APP QD Clinic: Difficult AxSpA
Philip Mease, MD and Christy Vath, PA-C, Seattle discuss a difficult to treat axial spondyloarthritis (axSpA) case. This APP QD clinic is presented as part of RheumNow's "Mission: APP Partners in Care" campaign during the month of December. https://t.co/qlBUtt6zWr
Dr. John Cush @RheumNow ( View Tweet)
Phase 1 trial of IL-6 targeting immunotherapy (PPV-06) in 24 pts w/ inflammatory knee osteoarthritis (KOA) demonstrates safety, Abs that neutralize IL-6, decreasing CRP values and improved clinical outcomes, determined by changes in KOOS scores https://t.co/urZupN62Kw https://t.co/sru1SnsOig
Links:
Dr. John Cush @RheumNow ( View Tweet)
Dr, Tuhina Neogi writes its time for a new understanding of OA; its not just wear n tear. Based on preclinical and clinical evidence, OA is a systemic, whole-body disease and that this should change future research and treatment of #OA. https://t.co/HQWI14WSXg https://t.co/5bIWgqaETU
Links:
Dr. John Cush @RheumNow ( View Tweet)
APP QD Clinic: Unweanable PMR APP QD Clinic: Unweanable PMR
Jack Cush, MD, and Leilani Law, APN, Dallas, TX, discuss a case regarding unweanable polymyalgia rheumatica. This APP QD clinic is presented as part of RheumNow's "Mission: APP Partners in Care" campaign during the https://t.co/Gl8iQJf1d2
Dr. John Cush @RheumNow ( View Tweet)
INITIAL Goal is to not miss Red Flag Conditions (Fx, septic or crystal arthritis [all acute monarticular})! Then provide timely Dx & Rx by establishing acute vs chronic, inflam vs noninflam, & articular vs nonarticular.
Dr. John Cush @RheumNow ( View Tweet)
Simple, low-cost strategy to Dx/Prognose GCA using CBC components NLR & PLR. 119 GCA vs 131 non-GCA pts - All CBC biomarkers signif assoc w/ ESR & CRP, but ESR/CRP did not predict mortality over time; YET mortality signif predicted by PLR, NLR, MLR (P value < 0.044) https://t.co/96Q7jDAiWt
Dr. John Cush @RheumNow ( View Tweet)
RHEUM Survey> What is the Sensitivity of the ANA test?
Dr. John Cush @RheumNow ( View Tweet)
OPD Spotter
Identify it before the patient even sits
Diagnosis ❓ https://t.co/xM90YEp9jZ
DocXus @docxusofficial ( View Tweet)
British Society of Rheumatology Guideline for Monitoring DMARDs
The British Society of Rheumatology has published an update to their previous 2017 BSR/BHPR guideline regarding the use and monitoring of DMARDs (disease-modifying anti-rheumatic drugs) used to treat systemic https://t.co/7KNf6cIjfo
Dr. John Cush @RheumNow ( View Tweet)
I agree that multiple assessments are needed to Dx NP-SLE; but my order of preference (for Dx yield) is: A) Hx c/w cerebritis; B) imaging to r/o other causes; C) CSF IgG index w/ Q albumin
Dr. John Cush @RheumNow ( View Tweet)
From the blog
Dr. Cush provides a systematic approach to evaluating musculoskeletal and rheumatic complaints in clinical practice.
Read Article
Podcasts
Focus on Guidelines
Preview of RheumNow Live 2026
QD Clinics - Mission: APP Partners in Care Week 1-
APPs in the news (12.05.25)
Therapeutic Updates
Underserved and Under-treated
RheumNow
Watch our Underserved and Under-Treated series as part of this month's Mission: APP Partners in Care campaign. Now available: Vaccine Pearls, Sex & The Rheumatology Patient, Pitfalls in Osteoporosis and Genesis & History of APPs.
Read Post
Poster Hall
Sponsored by AbbVie Medical Affairs + Health Impact
